- Home
- SXT vs PTGX Comparison
SXT vs PTGX Comparison
Compare SXT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXT
- PTGX
- Stock Information
- Founded
- SXT 1882
- PTGX 2006
- Country
- SXT United States
- PTGX United States
- Employees
- SXT N/A
- PTGX N/A
- Industry
- SXT Major Chemicals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SXT Industrials
- PTGX Health Care
- Exchange
- SXT Nasdaq
- PTGX Nasdaq
- Market Cap
- SXT 2.9B
- PTGX 2.8B
- IPO Year
- SXT N/A
- PTGX 2016
- Fundamental
- Price
- SXT $80.09
- PTGX $44.85
- Analyst Decision
- SXT Buy
- PTGX Strong Buy
- Analyst Count
- SXT 1
- PTGX 8
- Target Price
- SXT $85.00
- PTGX $66.50
- AVG Volume (30 Days)
- SXT 441.2K
- PTGX 1.3M
- Earning Date
- SXT 04-25-2025
- PTGX 05-06-2025
- Dividend Yield
- SXT 2.04%
- PTGX N/A
- EPS Growth
- SXT 33.03
- PTGX N/A
- EPS
- SXT 2.94
- PTGX 4.23
- Revenue
- SXT $1,557,228,000.00
- PTGX $434,433,000.00
- Revenue This Year
- SXT $3.84
- PTGX N/A
- Revenue Next Year
- SXT $4.39
- PTGX $7.13
- P/E Ratio
- SXT $27.28
- PTGX $10.62
- Revenue Growth
- SXT 6.92
- PTGX 624.05
- 52 Week Low
- SXT $66.15
- PTGX $24.22
- 52 Week High
- SXT $82.99
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- SXT 68.95
- PTGX 46.89
- Support Level
- SXT $72.60
- PTGX $45.07
- Resistance Level
- SXT $75.21
- PTGX $47.35
- Average True Range (ATR)
- SXT 2.94
- PTGX 2.51
- MACD
- SXT 0.65
- PTGX -0.01
- Stochastic Oscillator
- SXT 95.66
- PTGX 60.21
About SXT Sensient Technologies Corporation
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. The company has a widespread network of facilities around the globe, and its customers operate across a variety of end markets. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. The company's principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's three reportable segments were the Flavors & Extracts Group, the Color Group, and the Asia Pacific Group.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.